For example, elevated levels of phosphorylated HER2 in breast cancer have guided the addition of HER2-directed antibody–drug conjugates [91], while quantifying PD-L1 protein on tumor and immune cells has become routine to select patients for checkpoint blockade [92]. This evidence concerns the gene CD274 and breast carcinoma.